AIM
KYMR icon

Aigen Investment Management’s Kymera Therapeutics KYMR Stock Holding History

Aigen Investment Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,098
Closed -$708K – 665
2025
Q4 		$708K Sell
9,098
-2,779
-23% -$188K 0.16% 186
2025
Q3 		$672K Buy
+11,877
New +$536K 0.1% 305
2025
Q1 		– Sell
-5,069
Closed -$204K – 896
2024
Q4 		$204K Sell
5,069
-725
-13% -$32.7K 0.04% 606
2024
Q3 		$274K Sell
5,794
-1,990
-26% -$87.9K 0.05% 493
2024
Q2 		$232K Buy
+7,784
New +$270K 0.05% 582
2024
Q1 		– Sell
-9,162
Closed -$233K – 865
2023
Q4 		$233K Buy
+9,162
New +$164K 0.04% 606

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Aigen Investment Management's KYMR Position: Q1 2026 in Review

Aigen Investment Management sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 9,098 shares — an estimated $708K sold.

Aigen Investment Management first reported a position in KYMR in Q4 2023 and held it in 6 quarters. The position peaked at $708K in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Aigen Investment Management reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aigen Investment Management sold 9,098 Kymera Therapeutics shares in Q1 2026, an estimated $708K.
  • Aigen Investment Management first reported a position in Kymera Therapeutics in Q4 2023 and held it in 6 quarters.
  • Aigen Investment Management's Kymera Therapeutics position peaked at $708K in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.